Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
webinar

Rapid identification and characterisation of Affimer technology

Supported by:

8 October 2015

Affinity_and_specificity_cropped-1About this webinar

This webinar recording features a presentation by Avacta Life Sciences’ Chief Technology Officer Dr Matt Johnson. In it, he discusses Affimer® technology, a novel antibody mimetic and powerful antibody alternative. Plus:

  • Why Affimer technology has a number of key benefits over other affinity reagents.
  • How Avacta uses the IntelliCyt iQue device in its screening process.
  • A case study using Affimer technology to inhibit PD-L1, an immune check point protein expressed by tumor cells to trick t-cells into not destroying them.

This webinar was provided by Avacta Life Sciences

Our mission is to create a high quality, powerful set of tools to help Life Scientists accelerate the understanding of biology and disease and to help them apply these advances to diagnosis and treatment.

At Avacta Life Sciences we have developed the Affimer® , a revolutionary new alternative to antibodies and aptamers. Based on a small protein scaffold that can be engineered to bind with high specificity and affinity to a wide range of protein targets, Affimer reagents are engineered affinity proteins that are set to revolutionise the reagents market.

 

Access your FREE copy

 


Biomarkers aren’t just supporting drug discovery – they’re driving it

FREE market report

From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.

What you’ll unlock:

  • How biomarkers are guiding dose selection and early efficacy decisions in complex trials
  • Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
  • What makes lab data regulatory-ready and why alignment matters from day one

Explore how biomarkers are shaping early drug development

Access the full report – it’s free!

 

Affimer technology can be used for a wide range of applications in diagnostics, drug / biomarker discovery and biotech research & development. They can also act as therapeutic agents.

The rest of this content is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here